CM338
Phase 2Small molecule
CM338 is one of 30 small molecule programs targeting Nephropathy. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Theo-Dur
PfizerApproved
Rituxan
RocheApproved
Crestor
AstraZenecaApproved
Micardis
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zocor
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM338. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKeymed Biosciences Co.Ltd